Northwest Biotherapeutics (NASDAQ:NWBO), A increase of 494,412 shares or 3.9% was observed in the short interest of Northwest Biotherapeutics, Inc. The interest on June 15,2016 came in at 13,339,462 shares and as per the average daily trading of 798,595 shares, the days to cover are 17. The increased interest is 19.6% of the floated shares. The data of May 31,2016 put the interest at 12,845,050 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Northwest Biotherapeutics (NASDAQ:NWBO): The stock opened at $0.64 on Friday but the bulls could not build on the opening and the stock topped out at $0.69 for the day. The stock traded down to $0.57 during the day, due to lack of any buying support eventually closed down at $0.63 with a loss of -7.95% for the day. The stock had closed at $0.69 on the previous day. The total traded volume was 5,552,730 shares.
The company shares have dropped -93.46% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $12.55 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $0.79 and the 200 Day Moving Average price is recorded at $1.84.
Stocks of Northwest Biotherapeutics (NASDAQ:NWBO) rallied by 2.68% during the past week but lost 19.98% on a 4-week basis. The company has outperformed the S&P 500 by 4.38% in the past week but underperformed the index by 17.55% in the last 4 weeks.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Companys platform technology, DCVax, uses activated dendritic cells to mobilize a patients own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patients tumor. DCVax product lines are made from the patients own dendritic cells, which are freshly isolated, and matured and activated. The Companys DCVax product lines include DCVax-L, DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen, PSMA (Prostate Specific Membrane Antigen), which is found on all late stage prostate cancers.